Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.17 | 0.07 | -2.64 |
| FCF Yield | -30.89% | -26.29% | -10.19% | -4.07% |
| EV / EBITDA | -1.41 | -1.62 | -4.55 | -12.92 |
| Quality | ||||
| ROIC | -11.89% | -16.06% | -13.54% | -13.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -34.43% |
| Cash Conversion Ratio | 0.59 | 0.39 | 0.46 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 538,136.13% | 538,136.13% | 538,136.13% | 538,136.13% |
| Free Cash Flow Growth | -19.10% | 3.94% | 20.07% | 29.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | -0.08 | 0.09 | 0.27 |
| Interest Coverage | -51.02 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.02 |
| Cash Conversion Cycle | 15,479.57 | 9,594.57 | 11,517.32 | 1,928.74 |